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Bone nonunionAbstract Autologous bone grafting and ilizarov technique are the preferred mode of treatment for
bone nonunion, studies suggest that bone marrow derived mesenchymal stem cells can be effective
in treatment of tibial non-union where there is length of bone defect. The current study investigates
the beneficial clinical outcome of combining the ilizarov procedure with intraosseous injection of
autologous mesenchymal stem cells. The open-label study enrolled 25 patients with infected tibial
non-union at the Shanghai Fengxian District Central Hospital, Shanghai, China between April
2010 and July 2014. Patients were randomised to undergo the ilizarov procedure with (n= 11)
or without (n= 13) intraosseous injection of bone marrow derived mesenchymal stem cells. All par-
ticipants were followed prospectively until union was achieved (primary end point). The mean
length of the bone defect in the Ilizarov group and Ilizarov group plus MSC group was 6.09 and
5.84 cm respectively. The mean time from the original injury to the time of the treatment for tibial
non-union was 5–22 months (mean 13.5 months) for the Ilizarov group and 6–21 months (mean
13.5 months) for Ilizarov plus MSc group. All 24 patients were followed up for 12–34 months (mean
16 months). Both groups achieved the primary endpoint of stable union of the tibial fracture. No
adverse events were observed in any of the group. Our study demonstrates that using autologous
bone marrow derived mesenchymal stem cell as an add-on therapy to the ilizarov procedure shows
significant clinical benefit in fixation of tibial non-union.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nonunion of the tibia is frequently observed in the bone spe-
ciality setting and often leads to bone and soft tissue defect with
impaired quality of life in patients. Failure to correct this con-
dition may lead to chronic systemic infection or in prolonged
instances may even lead to amputation of the limb. In general,
any fracture that does not show union after 5–6 months isoutcome
2 H. Zhang et al.regarded as a nonunion and requires surgical intervention
(Rodriguez-Merchan and Forriol, 2004). There are high
chances of infection in an open fracture, and may lead to severe
complications such as osteoporosis, systemic infection, and per-
manent restriction of joint movement (Patzakis and Zalavras,
2005). Estimate suggests that around 10% of the patients with
compound fracture of long bone develop nonunion or delayed
union which results in severe impairment and multiple
instances of surgeries. The treatment of bone nonunion poses
a treatment challenge and requires a certain level of expertise
for successful treatment (Han et al., 2015; Kiratipaiboon
et al., 2015).
Conventional treatments, include autologous bone grafting
or artificial bone and metal grafting; however these proce-
dures are associated with operative wounds, bone defects,
incorrect union or nonunion and effective for bone defects
less than 4 cms (Motsitsi, 2008; Farmanullah et al., 2007).
Ilizarov external fixation technique, devised by Gavriil
Abramovich Ilizarov in 1951, is a popular procedure for the
treatment of bone nonunion, bone lengthening, and bone
deformity correction. This procedure has gained increasing
popularity in recent years and is extensively used by clinicians
worldwide for the treatment of compound fracture nonunion.
The procedures use metallic wires that are inserted percuta-
neously and attached to metallic ring to provide tension
and support to the bone (Ilizarov, 1989; Abdel-Aal, 2006;
Saridis et al., 2006). Illizarov procedure is also effective for
the treatment of long bone nonunion and improves early
weight bearing along with increasing the stability of the bone
union. However, the procedure requires a specialist to carry
out the procedure and also carries the risk that the bone
can be re-fractured if it takes a long time to heal and carries
the risk of infection at the site of wire insertion.
Other alternative procedures include use of bone marrow
derived mesenchymal stem cell injection to facilitate fast
healing of the bone (Connolly et al., 1991). The osteogenic
property of the bone marrow was first shown by Giujon
et al. in a rabbit model (Hernigou et al., 2005a). Thereafter
a number of studies have confirmed the osteogenic potential
of the bone marrow derived stem cells and bone marrow as
a whole. Studies have highlighted the use of mixing autolo-
gous with allogenic bone marrow can also be useful in
treatment of bone nonunion (Burwell, 1985; Lindholm and
Urist, 1980; Salama and Weissman, 1978; Desai et al.,
2015). Distal portion of long bone is usually rich in
haematopoietic bone marrow; however, it has been shown
that the red bone marrow is responsible for the physiologic
activity of the bone union. Various studies have confirmed
the role of bone marrow derived osteogenic precursor cells
in promoting healing of the bone. Parenteral administrations
of the bone marrow derived stem cells have been successfully
shown to promote healing of bone nonunion with minimum
systemic complications (Hernigou, 1998).
There is currently a lack of scientific evidence to demon-
strate beneficial clinical outcome of combining the ilizarov
procedure with intraosseous injection of autologous mesenchy-
mal stem cells. Therefore the current study has been under-
taken to evaluate the beneficial effect of the two procedures.
Our study tests the hypothesis that the combination of the
two procedures may have beneficial outcome on the quality
of union and reduce the time taken to achieve bone union.Please cite this article in press as: Zhang, H. et al., Ilizarov method in combination w
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2.1. Patient enrolment
A total of 25 patients with infected tibial non-union at the
Shanghai Fengxian District Central Hospital, Shanghai, China
hospital between April 2010 and July 2014 were enrolled in the
study. The study protocol was approved by the institutional
ethics committee of the Shanghai Fengxian District Central
Hospital, China and performed in accordance with the
declaration of Helsinki and International Conference on
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) Good Clinical Prac-
tice (E6) guidelines. A written informed consent for participa-
tion in the study was obtained from all participating patients.
A total of 31 patients were initially screened for the study;
however, only 25 qualified for the study based on the inclusion
criteria. Four patients could not be included in the study due
to concomitant systemic diseases or age more than 50 years;
two patients refused to participate in the study and opted for
the Ilizarov procedure outside the study. Patients were enrolled
based on the following inclusion criteria:
 Radiographically confirmed compound fracture of tibia
with diagnosis of tibia non-union.
 Male or female participants between ages of 18 and
50 years.
 The non-union gap should be between 3 and 12 cm.
 Subject or legal guardian is willing and able to understand,
sign and date the study specific Patient Informed Consent,
which has been approved by the Institutional Review
Board.
 Agrees to participate in post-operative evaluations and
required rehabilitation regimen.
Patients with following criteria were excluded from the
study:
 Age of the participant is more than 50 years.
 If female, participant is pregnant, plans on becoming preg-
nant during the duration of this clinical outcomes collection
study or lactating.
 Participant has an implanted unipolar pacemaker.
 Participant has active cancer.
 Participant has severe peripheral vascular disease
(ABI < 0.4)
 Participant is an established case of chronic diabetes.
A total of 25 patients with tibial non-union were ran-
domised to undergo the Ilizarov procedure in combination
with intraosseous injection of mesenchymal stem cells
(n= 13) or the Ilizarov procedure alone (n= 12). All partici-
pants were followed prospectively until union was achieved
(primary end point). In all patients, calcium and vitamin D
levels were checked after the initial procedure and treatment
was started if found to be low. All patients had vitamin D
levels of 30 lg/dL or more prior and during follow-up. At
the time of enrolment both anteroposterior (AP) and lateral
radiographs were taken. The radiographs were reviewed by
three independent orthopaedicians trained in orthopaedic
trauma surgery. Only patients whose radiograph was approvedith autologous mesenchymal stem cells from iliac crest shows improved outcome
.1016/j.sjbs.2016.11.001
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The length of bone defect (in cm) was measured as the largest
span between the two cortical fragments at the site of the
fracture.
2.2. Extraction and harvesting of mesenchymal stem cells
(MSCs)
All patients allocated to the Ilizarov procedure plus intraoss-
eous injection of MSC group were subjected to extraction pro-
cedure of obtaining bone marrow concentrate from the iliac
crest. The patient under lumbar epidural anaesthesia was
placed in a supine position on the operating table. The affected
long bone and the iliac crest of the same side were preferred for
bone marrow extraction. A small horizontal incision (0.5 cm)
was made at the anterior iliac crest to prevent any iatrogenic
injury to the iliac bone during insertion or withdrawal of the
trocar needle. Using a 16 gauge trocar needle an incision was
made into the cancellous bone between the inner and outer
tables of the iliac bone. Using a 50 ml syringe bone marrow
aspirate was withdrawn. The trocar needle was gently tilted
to 45 after every 10 ml of bone marrow extracted. Care was
taken to keep a distance of 2 cm apart during multiple
insertions and only 30 ml of bone marrow was withdrawn at
a time to prevent dilution with peripheral blood. The extracted
bone marrow was transferred through commercially available
mesenchymal stem cell extractor system, BMAC system (Bone
Marrow Procedure Pack; Harvest Technologies, Plymouth,
MA) from the aspiration syringe. The MSC harvest was
72  106 cells per ml (total Nucleated Cells/mL).
2.3. Ilizarov surgical procedure
Ilizarov procedure was performed under epidural anaesthesia
and preoperative parenteral cephalosporin was administered
to each patient. The standard ilizarov procedure was followed.
Ilizarov frames of stainless steel material (Suzhou Sunan
Zimmered Medical Instrument Co., Jiangsu, China), consist-
ing of three rings only for all patients, with 1.8-mm k-wire
and 3.5-mm Schanz were used. In majority of the patients
4–6 extension of 1 mm/day were performed. The ilizarov
fixation was removed only after callus mineralisation. Two
to three weeks of weight bearing was prescribed before the
external fixation was removed.
2.4. Intraosseous injection of autologous MSCs
Under biplane fluoroscopy the trocar needle was placed in the
non-union gap (Fig. 1). About 20 ml of MSC rich marrow was
injected at a rate of 20 ml/min. Care was taken to minimise the
leakage of the marrow and the position of the trocar needle
was changed if required. The perforation was closed using
surgical suture.
2.5. Statistical analysis
The primary end point of this study was time for union of the
tibial bone. Statistical significance was accepted for p-values of
<0.05. All analyses were performed using SigmaStat ver. 4.0
(Systat Software Inc., San Jose, CA, USA). To compare the
intergroup variation of the data a unidirectional analysis ofPlease cite this article in press as: Zhang, H. et al., Ilizarov method in combination w
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ple comparison.
3. Results
3.1. Patient characteristics
A total of 24 patients (17 male, 7 female; mean age 33.04 years)
with tibia non-union were enrolled in the study; 12 patients
were allocated to the Ilizarov procedure for union of tibial
fracture and 13 patients were allocated to Ilizarov procedure
in combination with intraosseous injection of autologous mes-
enchymal stem cells (Fig. 2). The mean length of the bone
defect in the Ilizarov group and Ilizarov group plus MSC
group was 6.09 and 5.84 cm respectively. Patient demographics
and clinical profile are represented in Table 1. The mean time
from the original injury to the time of the treatment for tibial
non-union was 5–22 months (mean 13.5 months) for the
Ilizarov group and 6–21 months (mean 13.5 months) for
Ilizarov plus MSc group. All 24 patients were followed up
for 12–34 months (mean 16 months). Both groups achieved
the primary endpoint of stable union of the tibial fracture.
No adverse events were observed in any of the groups;
however 2 patients in the Ilizarov group and 3 patients in
the Ilizarov plus MSC group reported minor infection at the
pin site, which was controlled by systemic and topical antibi-
otics. One patient in the Ilizarov group reported skin allergy
which was controlled with oral antihistamine.
There was a significant decrease in the time taken for union
of the tibia fracture in MSC plus the Ilizarov group as com-
pared to the Ilizarov group alone (P= 0.006). The mean dura-
tion for bone union was 6.45 months in patients undergoing
Ilizarov procedure alone and 3.92 months in patients undergo-
ing a combination of the Ilizarov procedure and intraosseous
injection of autologous MSC. The external fixation index
(days/cm) in the Ilizarov plus MSC group was 22.83 compared
with 34.13 in the Ilizarov only procedure group (P= 0.016)
(Fig. 3). There was also a significant decrease in the duration
of hospitalisation in patients who underwent the Ilizarov pro-
cedure in combination with intraosseous injection of autolo-
gous MSC (P= 0.025). Paley score was excellent in majority
of the patients in both groups. Mean values of clinical and
demographic parameters are represented in Table 2. The count
of MSC in extracted bone marrow was 45 x 106 cells whereas
the CFU count per millilitre in aspirate was 210 ± 126.
4. Discussion
The current study gathers evidence from a randomised clinical
study on the beneficial effect of adding autologous mesenchy-
mal stem cell procedure to the established Ilizarov procedure.
In recent years the Illizarov procedure has become treatment
of choice for infected bone nonunion; however it requires the
patient to have restricted movement due to the bulky metallic
frame and inserted wires. Adding a complimentary therapy/
procedure to reduce the duration of Ilizarov would be much
welcomed by patients. There may be several causes of bone
union, such as high impact injury, damage to blood supply,
infection of the open wound and low levels of calcium.
Infection is a major risk associated with the ilizarov procedure
and may cause osteoporosis, restriction of joint movement andith autologous mesenchymal stem cells from iliac crest shows improved outcome
.1016/j.sjbs.2016.11.001
Figure 1 (A) Bone marrow aspirate was obtained from posterior iliac crest using a trocar needle and then passed through mesenchymal
stem cell extractor system (B) Intraosseous injection of MSC rich bone marrow under biplane fluoroscope (C) Illizarov external fixator
surrounding the tibial bone (D) X-ray of tibia after the Ilizarov fixator was placed.
4 H. Zhang et al.cutaneous deficiency (Green et al., 1992). As per clinical Clas-
sification of post-traumatic tibial osteomyelitis by May, bone
graft is preferred for bone defects <6 cm, for defects >6 cm
bone grafting possesses several challenges (May et al., 1989).
The conventional osteodistraction procedure was first
developed in 1950. The procedure requires generation of
muscle, aponeurosis, nervous tissue and integumentary tissue,
due to the distraction of the bone. In due course of time the
physical stress causes remodelling and bone union. Ilizarov
technique is an expansion of this procedure and addresses
much of the complications and drastically improves the quality
of the union (Ilizarov, 1989). Ilizarov procedure also enables
free access to the site of injury to monitor rate of healing
and infection. Some of the significant highlights of this proce-Please cite this article in press as: Zhang, H. et al., Ilizarov method in combination w
in tibial non-union. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10dure are: The tension of the wire needs to be proportional to
the diameter of the wire, that keeps the bone in place; in a
week’s time extension of the bone should be visible; period
X-ray examination should be performed to monitor the bone
union and fixation; partial weight bearing activity may be
resumed during the extension phase. The recommended ten-
sion and wire diameter for the ilizarov fixator is 1–2  103 N
and 2 mm respectively (Mullins et al., 2003). During the long
period of extension phase the steel wires may become weak
and break, therefore the time required for keeping the external
fixator on a patient’s bone becomes critical.
Our study addresses this concern as we used autologous
MSC to combine with the ilizarov procedure to reduce the time
taken to achieve bone union. We included all patients with theith autologous mesenchymal stem cells from iliac crest shows improved outcome
.1016/j.sjbs.2016.11.001
Figure 2 Study schema showing flow of patients in each stage of the trial.
Table 1 Demographics and clinical profile of each patient from both groups.
S.
No.
Group Patient
ID
Age
(Years)
Sex Length of
bone
defect (in
cm)
Duration
of follow-
up
(months)
Duration of
Hospitalisation
(months)
Time taken
for union of
fracture
(months)
Duration of
external
fixation
(months)
External
fixation
index
(days/cm)
Paley
score
1 Ilizarov
Group
1XA 34 M 3 12 2 3 4 30 Excellent
2 1 KB 42 M 9 18 4 6 8 20 Excellent
3 1NC 19 F 7 20 5 6 7 25.7143 Good
4 1TD 37 M 4 15 2.5 4 5 30 Excellent
5 1XE 23 M 5 12 6 8 7 48 Good
6 1RF 40 M 3 12 3 5 5.5 50 Excellent
7 1XG 49 F 7 32 6 9 11 38.5714 Excellent
8 1JH 22 F 9 12 4 11 12 36.6667 Excellent
9 1XI 28 M 10 28 6 8 9 24 Good
10 1SJ 43 F 4 14 5 7 7.5 52.5 Excellent
11 1FK 31 M 6 14 2.5 4 6 20 Excellent
1 Ilizarov
+MSC
1LA 26 M 4 12 2 3 3.5 22.5 Excellent
2 1QB 35 F 9 12 3 4 4.5 13.3333 Excellent
3 1YC 48 M 3 12 1.5 4 5 40 Excellent
4 1MD 18 M 3 12 2 3 3.5 30 Excellent
5 1YE 27 M 6 14 3 3 4 15 Excellent
6 1GF 31 M 8 12 5 6 7 22.5 Excellent
7 1YG 36 F 4 12 3 5 8 37.5 Excellent
8 1PH 28 M 6 12 2 4 5 20 Excellent
9 1CI 41 M 7 20 2 3 4 12.8571 Excellent
10 1YJ 39 M 11 34 6 6 6.5 16.3636 Good
11 1BK 29 M 7 18 1.5 3 4 12.8571 Excellent
12 1UL 30 M 3 12 2 3 4 30 Excellent
13 1HM 37 F 5 13 3 4 5 24 Excellent
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Table 2 Comparative clinical and demographic parameters
between the two groups.
Ilizarov
procedure
Group
Ilizarov
+MSC
P value
Mean age 33.45 32.69
Mean bone defect (in cm) 6.09 5.84
Male 7 10
Female 4 3
The time of follow-up
(months)
17.82 15 P= 0.325
The time in hospital (months) 4.18 2.7 P= 0.025
Time taken for union of
fracture (months)
6.45 3.92 P= 0.006
Duration of external fixation
(months)
7.45 4.92 P= 0.011
External fixation index
(days/cm)
34.132 22.83 P= 0.016
Figure 3 External fixation index (days/cm) of each patient from
both groups.
6 H. Zhang et al.size of the bone defect within 3–12 cm, which gave us the scope
to test our hypothesis in varied types of non-unions. Our study
also demonstrates a reduction in the duration of achieving
bone union by 2.5 months which is statistically significant.
There is no such study available that utilises MSCs for the
bone defect range that we used in our study. In another study
by Desai et al. the time for bone union was found to be
4.7 months; however this study used MSCs as a standalone
procedure (Desai et al., 2015). Other parameters which showed
statistically significant benefit were duration of hospitalisation
(months) and external fixation index (days/cm). The combina-
tion of commercially available demineralised bone matrix with
mesenchymal stem cells have shown comparable results in
bone union in both preclinical and clinical studies but it does
not show a significant reduction in the time taken for healing
(Hernigou et al., 2005b; Sen and Miclau, 2007). Studies also
suggest that combination of allogeneic graft of rhBMP-2 with
autologous bone marrow shows a rate of around 90%,
however our study achieved 100% results with significant
reduction in the number of parameters.Please cite this article in press as: Zhang, H. et al., Ilizarov method in combination w
in tibial non-union. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/105. Conclusion
Our study has successfully demonstrated that using autologous
bone marrow derived mesenchymal stem cells as an add-on
therapy to the ilisarov procedure shows significant clinical
benefit in fixation of tibial nonunion. The study utilised a com-
mercially available device for isolation of mesenchymal stem
cells; further characterisation of the stem cell population needs
to be performed. The study also warrants a larger clinical trial
in different types of bone unions to highlight the beneficial out-
come of combination approach.
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